Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferPreservative: 0.02% Thimerosal (merthiolate)
Constituents: 50% Glycerol, 1% BSA, PBS, pH 7.2
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab18841 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 - 4 µg/ml. Detects a band of approximately 120 kDa.|
|IP||Use a concentration of 20 µg/ml.|
|IHC-Fr||Use a concentration of 20 µg/ml.|
FunctionInhibitory regulator of the Ras-cyclic AMP pathway. Stimulates the GTPase of normal but not oncogenic Ras p21.
Tissue specificityIn placental villi, detected only in the trophoblast layer (cytotrophoblast and syncytiotrophoblast). Not detected in stromal, endothelial or Hofbauer cells (at protein level).
Involvement in diseaseNote=Mutations in the SH2 domain of RASA seem to be oncogenic and cause basal cell carcinomas.
Defects in RASA1 are the cause of capillary malformation-arteriovenous malformation (CMAVM) [MIM:608354]. CMAVM is a disorder characterized by atypical capillary malformations that are multiple, small, round to oval in shape and pinkish red in color. These capillary malformations are associated with either arteriovenous malformation, arteriovenous fistula, or Parkes Weber syndrome.
Defects in RASA1 are a cause of Parkes Weber syndrome (PKWS) [MIM:608355]. PKWS is a disorder characterized by a cutaneous flush with underlying multiple micro-arteriovenous fistulas, in association with soft tissue and skeletal hypertrophy of the affected limb.
Sequence similaritiesContains 1 C2 domain.
Contains 1 PH domain.
Contains 1 Ras-GAP domain.
Contains 2 SH2 domains.
Contains 1 SH3 domain.
modificationsThe N-terminus is blocked.
- Information by UniProt
- CM AVM antibody
- CMAVM antibody
- DKFZp434N071 antibody
ab18841 has not yet been referenced specifically in any publications.